Researchers at MUSC Hollings Cancer Center and international collaborators have developed a new blood test that could help patients at high risk for lymphoma get to a biopsy and treatment sooner. The Access to Diagnosis using Liquid Biopsy (ADLiB) platform combines multiple genetic clues found in the blood with machine learning to estimate a patient’s likelihood of having lymphoma. In an initial study of 124 patients in South Africa, the platform correctly identified patients with lymphoma 95% of the time. Rather than replacing a tissue biopsy, researchers envision ADLiB as a tool to fast-track patients who need further testing, particularly in rural and resource-limited settings where access to specialized pathology expertise may be limited.